The Plot Thickens: More on Belatacept Outcomes in Obesity

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/90/83/17/90831762-6e15-040f-590b-662a2eb9a7f6/mza_3030779015651081576.jpg/600x600bb.jpg

The mTOR You Know

102 episodes

4 days ago

The mTOR you know is a solid organ transplant podcast produced by the ACCP Transplant PRN. Please follow @themTORyouknow on X!

Medicine

Health & Fitness

RSS

All content for The mTOR You Know is the property of The mTOR You Know and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

The mTOR you know is a solid organ transplant podcast produced by the ACCP Transplant PRN. Please follow @themTORyouknow on X!

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/3610431/3610431-1584069058057-5a13e7e634351.jpg

The Plot Thickens: More on Belatacept Outcomes in Obesity

The mTOR You Know

31 minutes 33 seconds

9 months ago

The Plot Thickens: More on Belatacept Outcomes in Obesity

Drs. Nick Lange and Dave Salerno join us to discuss their team's recently published paper taking an in-depth look at the relationship between obesity and outcomes in patients on belatacept-based immunosuppression. To follow along, their article can be found via the following citation:

Lange NW, King K, Husain SA, Salerno DM, Tsapepas DS, Hedvat J, Yu M, Mohan S. Obesity is associated with a higher incidence of rejection in patients on belatacept: A pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials. Am J Transplant. 2024 Jun;24(6):1027-1034. doi: 10.1016/j.ajt.2024.02.015. Epub 2024 Feb 21. PMID: 38387620.

This episode is a follow-up to our December 2023 clinical debate on immunosuppression dosing in the setting of obesity. If you missed it or need a refresher, we encourage you to listen to that episode as well.